

RECEIVED

JUN 06 2002


SHEET 1 OF 1

INFORMATION DISCLOSURE CITATION IN AN APPLICATION			ATTN: TECH CENTER 1600/2000 50193-109	SERIAL NO. 09/892,505		
			APPLICANT Salah D. KIVLIGHN, et al.			
			FILING DATE June 28, 2001	GROUP 1614		
U.S. PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
<i>PC</i>	4,510,322	4/9/85	Blaine et al.	514	255	
<i>PC</i>	4,296,122	10/20/81	Cragoe, Jr. et al.	424	285	
FOREIGN PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation
						Yes
<i>PC</i>	EP 000128	6/8/78	Europe			
<i>PC</i>	EP 415566	7/31/90	Europe			
<i>PC</i>	WO 93 04688	3/18/93				
<i>PC</i>	DE 2707270	2/19/77	Germany			
<i>PC</i>	DE 2707269	2/19/77	Germany			
<i>PC</i>	EP 0 104483	8/31/83	Europe			
<i>PC</i>	WO 00 07629	2/17/00				
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
<i>PC</i>	L.M. Burrell, "A risk-benefit assessment of Losartan potassium in the treatment of hypertension", Drug Safety, Vol. 16, no. 1, 1997, pages 56-65.					
<i>PC</i>	T. Gibson E.A.; "Tienilic acid in the treatment of gout and hypertension", Advances in Experimental Medicine and Biology", Vol. 122A, 1980 pages 277-282.					
EXAMINER	DATE CONSIDERED <i>12/11/03</i>					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE
CITATION IN AN
APPLICATION

(PTO-1449)

ATTY. DOCKET NO.
50193-109SERIAL NO.
09/892,505JUL 23 2002
TECH CENTER 1600/2900APPLICANT
Salah D. KIVLIGHN, et al.FILING DATE
June 28, 2001GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

WU, X. et al; Two Independent Mutational Events Resulted in the Loss of Urate Oxidase During Hominoid Evolution, J. Mol. Evol.34:78-84 (1992);
EATON, S.B. et al; A Consideration of its Nature and Current Implications, N. Engl J Med 312:283-289 (1985);
CANNON, P.J. et al; Hyperuricemia in Primary and Renal Hypertension, N Engl J Med 275:457-464 (1966);
HAIG, A., On Uric Acid and Arterial Tension, Br Med J 1:288-291 (1889);
SELBY, J.V. et al, Precursors of Essential Hypertension: Pulmonary Function, Heart Rate, Uric Acid, Serum Cholesterol, and Other Serum Chemistries, Am J Epidemiol 131:1017-27 (1990);
JOSSA, F. et al, Serum Uric Acid and Hypertension: The Olivetti Heart Study, J Hum Hypertens 8:677-681 (1994);
GOLDSTEIN, H.S. et al, Relationship Between Serum Uric Acid and Blood Pressure in Adolescents, Annals Hum Biol 20:423-431(1993);
FANG, J. et al, Serum Uric Acid and Cardiovascular Mortality, The NHANES I Epidemiologic Follow-up Study, 1971-1992, JAMA 283:2404-2410 (2000);

EXAMINER

DATE CONSIDERED

1/21/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

3

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)			ATTY. DOCKET NO. 50193-109	SERIAL NO. 09/892,505		
			APPLICANT Salah D. KIVLIGHN, et al.	JUL 23 2002 USPTO RECEIVED JUL 22 2002 PATENT & TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE		
			FILING DATE June 28, 2001	GROUP 1614		
U.S. PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
FOREIGN PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation
						Yes No
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
<i>[Signature]</i>	BENGTSSON, C. et al, Hyperuricemia and Risk of Cardiovascular Disease and Overall Death, Acta Med Scand 224:549-55 (1988);					
	ALDERMAN, M.H. et al, Serum Uric Acid and Cardiovascular Events in Successfully Treated Hypertensive Patients, Hypertension 34:144-150 (1999)					
	LEHTO, S. et al, Serum Uric Acid is a Strong Predictor of Stroke in Patients with Non-Insulin Dependent Diabetes Mellitus, Stroke 29:635-639 (1998);					
	PERSKY, V.W. et al, Uric Acid: A risk Factor for Coronary Heart Disease? Circulation 59:969-979 (1979);					
	VACCARINO, V. et al, Risk Factors for Cardiovascular Disease: One Down, Many More to Evaluate, Ann Int Med 131:62-63 (1999);					
	WANNAMETHEE, S.G., Is Serum Uric Acid a Risk Factor for Coronary Heart Disease? J Hum Hypertens 13:153-156 (1999);					
EXAMINER <i>[Signature]</i>	DATE CONSIDERED <i>1/21/03</i>					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)			ATTY. DOCKET NO. 50193-109	SERIAL NO. 09/892,568		
			APPLICANT Salah D. KIVLIGHN, et al.	SEARCH CENTER 1600/2000 JUL 23 2002 RECEIVED		
			FILING DATE June 28, 2001		GROUP 1614	
U.S. PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
FOREIGN PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation
						Yes
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
<p>Keith A. Barlow, "Hyperlipidemia in Primary Gout", Department of Pathology, King's College Hospital Medical School, London, England, pp. 289-299. <i>DATE Needed</i></p> <p>R. Grahame et al., "Clinical survey of 354 patients with gout", Ann. Rheum. Dis. (1970), 29, pp. 461-468.</p> <p>Bruce F. Cullen, MD, et al., "Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study", Ann Intern Med., 1999, 131, pp. 7-13.</p> <p>Ronald Klein, MD, et al., "Serum Uric Acid: Its Relationship to Coronary Heart Disease Risk Factors and Cardiovascular Disease, Evans, County, Georgia, Arch Intern Med/ Vol. 132, Sept 1973, pp. 401-410.</p> <p>Katsuhiko Yano, et al., "Ten-Year Incidence of Coronary Heart Disease in the Honolulu Heart Program, American Journal of Epidemiology, Vol. 119, No. 5, May 1984, pp. 653-665.</p> <p>"Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy", Kidney International, Vol. 50, 1996, pp. 1089-1100.</p> <p>Bryan D. Myers et al., "Cyclosporine-Induced Chronic Nephropathy: An Obliterative Microvascular Renal Injury", Journal of the American Society of Nephrology, Vol. 2, Supplement 1, 1991, pp. 45-52.</p> <p>J.R. Chapman et al., "Reversibility of Cyclosporin Nephrotoxicity After Three Months' Treatment, the Lancet, January 19, 1985, pp. 128-129, 308-313.</p> <p>Paul R. Gores, M.D., et al., "Hyperuricemia After Renal Transplantation", The American Journal of Surgery, Vol. 156, November 1988, pp. 397-400.</p>						
EXAMINER <i>[Signature]</i>	DATE CONSIDERED <i>1/21/03</i>					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)		ATTY. DOCKET NO. 50193-109	SERIAL NO. 09/892,503
APPLICANT Salah D. KIVLIGHN, et al.			
FILING DATE June 28, 2001		GROUP 1614	<i>JUL 23 2002 RECEIVED U.S. PATENT AND TRADEMARK OFFICE JUL 22 2002</i>

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>p</i>	Leslie E. Kahl, M.D., et al., "Gout in the Heart Transplant Recipient: Physiologic Puzzle and Therapeutic Challenge", The American Journal of Medicine, Vol. 87, September 1989, pp. 289-294.
	John S. Najarian, M.D., et al., "A Single Institution, Randomized, Prospective Trial of Cyclosporine Versus Azathioprine-Antilymphocyte Globulin for Immunosuppression in Renal Allograft Recipients", The University of Minnesota Health Sciences Center, Vol. 201, No. 2, pp. 142-157. <i>No date</i>
<i>W</i>	David E.R.Sutherland et al., "Results of the Minnesota Randomized Prospective Trial of Cyclosporine Versus Azathioprine-Antilymphocyte Globulin for Immunosuppression in Renal Allograft Recipients", American Journal of Kidney Diseases, Vol. V, No. 6, June 1985, pp. 318-327.
	Cynthia West, MD, et al., "The Incidence of Gout in Renal Transplant Recipients", American Journal of Kidney Disease, Vol. X, No. 5, November 1987, pp. 369-371.
	R.M. Zurcher, et al., "Hyperuricaemia in cyclosporin-treated patients: a GFR-related effect", 1996 European Dialysis and Transplant Association-European Renal Association, 1996, 11: pp. 153-158.
<i>✓</i>	Jarmo Laine, et al., "Mechanisms of Hyperuricemia in Cyclosporine-Treated Renal Transplanted Children", Nephron, 1996, 74: pp. 318-323.

EXAMINER


DATE CONSIDERED

1/21/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and consider. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE
CITATION IN AN
APPLICATION

(PTO-1449)

ATTY. DOCKET NO.
50193-109SERIAL NO.
09/892,505

RECEIVED
JUL 23 2002
SEARCH CENTER 1600/2900

APPLICANT
Salah D. KIVLIGHN, et al.FILING DATE
June 28, 2001GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	R. Marcen et al., "Impairment of Tubular Secretion of Urate in Renal Transplant Patients on Cyclosporine", Nephron 1995, 70:, pp. 307-313.
	Bryan D. Myers, "Cyclosporine nephrotoxicity", Kidney International, Vol. 30, 1986, pp. 964-974.
	W.M. Bennett, et al., "Nephrotoxicity of immunosuppressive drugs", Nephrol Dial Transplant, 1994 9, Supp. 4:, pp. 141-145.
	Emmanuel A. Burdmann, et al., "Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril", The American Physiological Society, 1999, pp. F194-499.
	Raimund H. Pichler ² , et al., "Pathogenesis of Cyclosporine Nephropathy: Roles of Angiotensin II and Osteopontin", Journal of American Society of Nephrology, Vol. 6, No. 4, 1995, pp. 1186-1196.
	Peter F. Hoyer, et al., "Renal handling of uric acid under cyclosporin A treatment", Pediatric Nephrology, 1988, 2, pp. 18-21.
	Franz H. Messerli, M.D., et al., "Serum Uric Acid in Essential Hypertension: An Indicator of Renal Vascular Involvement", Annals of Internal Medicine, 1980, 93: pp. 817-821.
	Laurence H. Beck, "Requiem for gouty nephropathy", Kidney International, Vol. 30, 1986, pp. 280-287.
	"An evaluation of the pathogenesis of the gouty kidney", Kidney International, Vol. 8, 1975, pp. 65-71.
	Richard J. Johnson, M.D., et al. "Reappraisal of the Pathogenesis and Consequences of Hyperuricemia in Hypertension, Cardiovascular Disease, and Renal Disease", American Journal of Kidney Diseases, Vol. 33, No. 2, February 1999, pp. 225-234.

EXAMINER

DATE CONSIDERED

1/23/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE
CITATION IN AN
APPLICATION

(PTO-1449)

ATTY. DOCKET NO.
50193-109SERIAL NO.
09/892,585APPLICANT
Salah D. KIVLIGHN, et al.FILING DATE
June 28, 2001GROUP
1614

RECEIVED
TECH CENTER 1600 JUL 23 2002

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	V. Nickeleti et al., "Uric acid nephropathy and end-stage renal disease - Review of a non-disease", Nephrol Dial Transplant, 1997, 12, pp. 1832-1838.
	Ts'ai-Fan Yü, M.D., "Renal Function in Gout: V. Factors Influencing the Renal Hemodynamics", The American Journal of Medicine, November 1979, Vol. 67, pp. 766-771.
	Sônia M. A. Assis ² , et al., "L-Arginine and Allopurinol Protect Against Cyclosporine Nephrotoxicity ¹ ", Transplantation, Vol. 63, April 27, 1997, Vol. 63, pp. 1070-1073.
	Bernhard F. Becker, "Towards the Physiological Function of Uric Acid, Free Radical Biology and Medicine, Vol. 14, 1993, pp. 615-631,
	Jerry Waisman, M.D., "A Preliminary Report of Nephropathy in hyperuricemic Rats, Laboratory Investigation, Vol. 30, No. 6, 1974, pp. 716-722.
	John H. Talbott, M.D., et al., "The Kidney in Gout", Department of Medicine and Pathology, University of Buffalo School of Medicine and the Buffalo General Hospital, pp. 405-467. <i>No date</i>
	Harvey C. Gonick, M.D., "The Renal Lesion in Gout", Vol. 62, No. 4, April 1965, pp. 667-674.
	Lawrence Berger, M.D., et al., "Renal Function in Gout: IV. An Analysis of 524 Gouty Subjects Including Long-Term Follow-Up Studies*", The American Journal of Medicine, Vol. 59, November 1975, pp. 605-613.

EXAMINER

DATE CONSIDERED

1/21/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)			ATTY. DOCKET NO. 50193-109	SERIAL NO. 09/892,505		
			APPLICANT Salah D. KIVLIGHN, et al.	JUL 23 2002 TECH CENTER 1600/2900		
			FILING DATE June 28, 2001	GROUP 1614		
U.S. PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
FOREIGN PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation
						Yes
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
	David Greenbaum, M.B., M.R.C.P., "Renal Biopsy in Gout", British Medical Journal, May 27, 1961, pp. 1502-1504.					
	Ts'ai-Fan Yü, M.D., et al., "Impaired Renal Function in Gout" Its Association with Hypertensive Vascular Disease and Intrinsic Renal Disease", The American Journal of Medicine, Vol. 72, January 1982, pp. 95-100.					
	F. Perez-Ruiz, et al., "Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout", Am. Rheum. Dis, 1995, 57, pp. 545-549.					
	W. Jeffrey Fessel, M.D., "Renal Outcomes of Gout and Hyperuricemia, The American Journal of Medicine, Vol. 67, July 1979, pp. 74-82.					
	Joseph B. Rosenfeld, "Effect of Long-Term Allopurinol Administration on Serial GFR in Normotensive and Hypertensive Hyperuricemic Subjects", Dept. of Medicine and Renal Unit, eilinson Medical Center, Petah Tikvah, Israel, Tel-Aviv, University Medical School, pp. 581-596. <i>Date needed</i>					
	Marilda Mazzali, et al., "Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure independent mechanism", Am. J. Physiol. Renal Physiol 282, pp. F991-997. Marilda Mazzali, et al., "Elevated Uric Acid Increases Blood Pressure in the Rat by a Novel Crystal-Independent Mechanism", pp. 1101-1106. <i>Date needed</i>					
EXAMINER 	DATE CONSIDERED <i>1/21/03</i>					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.